Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine, with or without aura~* At least moderate pain with migraines~* Average of 2 to 6 migraines per month for past 3 months~* Duration of headache pain at least 4 hours~* Able to tell the difference between a migraine and a tension headache~* If taking a medication to prevent migraines, patients must have been taking a maintenance dose for at least 30 days before screening~* In generally good health~* If female, using birth control~Exclusion Criteria:~* Routinely experience other type of headache that might seem like a migraine headache~* An average of 15 or more headache days per month in the past 6 months~* Migraines began after age 50~* Taking \> 1 medicine for preventing migraines~* Use of any drugs on list of prohibited drugs, of opioid drugs in past 7 days, of corticosteroids in the past 30 days, of an investigational drug within 30 days~* Use of non-drug treatment for migraine in past 14 days unless have used this treatment for \> 14 days and plan to continue throughout study~* Overuse of medications that treat pain or nausea~* Migraine aura without headache~* Hemiplegic or basilar migraines~* Usually have vomiting with headache~* Headaches that usually occur upon waking~* Significant unstable medical disease~* Abnormal liver, kidney, blood, or ECG laboratory or test results~* Abusing drugs or alcohol~* History of a significant mental disorder~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).